Literature DB >> 25441017

Excess length of stay and mortality due to Clostridium difficile infection: a multi-state modelling approach.

E van Kleef1, N Green2, S D Goldenberg3, J V Robotham4, B Cookson5, M Jit6, W J Edmunds7, S R Deeny4.   

Abstract

BACKGROUND: The burden of healthcare-associated infections, such as healthcare-acquired Clostridium difficile (HA-CDI), can be expressed in terms of additional length of stay (LOS) and mortality. However, previous estimates have varied widely. Although some have considered time of infection onset (time-dependent bias), none considered the impact of severity of HA-CDI; this was the primary aim of this study.
METHODS: The daily risk of in-hospital death or discharge was modelled using a Cox proportional hazards model, fitted to data on patients discharged in 2012 from a large English teaching hospital. We treated HA-CDI status as a time-dependent variable and adjusted for confounders. In addition, a multi-state model was developed to provide a clinically intuitive metric of delayed discharge associated with non-severe and severe HA-CDI respectively.
FINDINGS: Data comprised 157 (including 48 severe) HA-CDI cases among 42,618 patients. HA-CDI reduced the daily discharge rate by nearly one-quarter [hazard ratio (HR): 0.72; 95% confidence interval (CI): 0.61-0.84] and increased the in-hospital death rate by 75% compared with non-HA-CDI patients (HR: 1.75; 95% CI: 1.16-2.62). Whereas overall HA-CDI resulted in a mean excess LOS of about seven days (95% CI: 3.5-10.9), severe cases had an average excess LOS which was twice (∼11.6 days; 95% CI: 3.6-19.6) that of the non-severe cases (about five days; 95% CI: 1.1-9.5).
CONCLUSION: HA-CDI contributes to patients' expected LOS and risk of mortality. However, when quantifying the health and economic burden of hospital-onset of HA-CDI, the heterogeneity in the impact of HA-CDI should be accounted for.
Copyright © 2014 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clostridium difficile infection; Length of hospital stay; Mortality

Mesh:

Year:  2014        PMID: 25441017     DOI: 10.1016/j.jhin.2014.08.008

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  12 in total

1.  Inpatient Expenditures Attributable to Hospital-Onset Clostridium difficile Infection: A Nationwide Case-Control Study in Japan.

Authors:  Haruhisa Fukuda; Takahisa Yano; Nobuyuki Shimono
Journal:  Pharmacoeconomics       Date:  2018-11       Impact factor: 4.981

Review 2.  Expanding the statistical toolbox: analytic approaches for cohort studies with healthcare-associated infectious outcomes.

Authors:  Rebecca A Pierce; Justin Lessler; Aaron M Milstone
Journal:  Curr Opin Infect Dis       Date:  2015-08       Impact factor: 4.915

3.  Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital.

Authors:  Marie Pichenot; Rozenn Héquette-Ruz; Remi Le Guern; Bruno Grandbastien; Clément Charlet; Frédéric Wallet; Sophie Schiettecatte; Fanny Loeuillet; Benoit Guery; Tatiana Galperine
Journal:  Infection       Date:  2017-01-24       Impact factor: 3.553

4.  Estimating Local Costs Associated With Clostridium difficile Infection Using Machine Learning and Electronic Medical Records.

Authors:  Theodore R Pak; Kieran I Chacko; Timothy O'Donnell; Shirish S Huprikar; Harm van Bakel; Andrew Kasarskis; Erick R Scott
Journal:  Infect Control Hosp Epidemiol       Date:  2017-11-06       Impact factor: 3.254

5.  THAs Performed Within 6 Months of Clostridioides difficile Infection Are Associated with Increased Risk of 90-Day Complications.

Authors:  Scott J Douglas; Ethan A Remily; Oliver C Sax; Sahir S Pervaiz; Evan B Polsky; Ronald E Delanois
Journal:  Clin Orthop Relat Res       Date:  2021-12-01       Impact factor: 4.176

Review 6.  Systematic Review of Prognostic Factors for Return to Work in Workers with Sub Acute and Chronic Low Back Pain.

Authors:  Ivan A Steenstra; Claire Munhall; Emma Irvin; Nelson Oranye; Steven Passmore; Dwayne Van Eerd; Quenby Mahood; Sheilah Hogg-Johnson
Journal:  J Occup Rehabil       Date:  2017-09

7.  Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness.

Authors:  Oliver A Cornely; Maureen Watt; Charles McCrea; Simon D Goldenberg; Enrico De Nigris
Journal:  J Antimicrob Chemother       Date:  2018-09-01       Impact factor: 5.790

8.  Estimating extra length of stay and risk factors of mortality attributable to healthcare-associated infection at a Chinese university hospital: a multi-state model.

Authors:  Qian Zhou; Lili Fan; Xiaoquan Lai; Li Tan; Xinping Zhang
Journal:  BMC Infect Dis       Date:  2019-11-20       Impact factor: 3.090

9.  The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations.

Authors:  S D Goldenberg; S Brown; L Edwards; D Gnanarajah; P Howard; D Jenkins; D Nayar; M Pasztor; S Oliver; T Planche; J A T Sandoe; P Wade; L Whitney
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-12-12       Impact factor: 3.267

10.  Excess length of hospital stay, mortality and cost attributable to Clostridioides (Clostridium) difficile infection and recurrence: a nationwide analysis in Japan.

Authors:  T Kimura; S Stanhope; T Sugitani
Journal:  Epidemiol Infect       Date:  2020-03-02       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.